Rep. Josh Gottheimer Sells Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM). In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Tandem Diabetes Care stock on March 19th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

  • Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 3/24/2025.
  • Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 3/24/2025.
  • Sold $1,001 – $15,000 in shares of Flywire (NASDAQ:FLYW) on 3/19/2025.
  • Sold $1,001 – $15,000 in shares of Disco (OTCMKTS:DSCSY) on 3/19/2025.
  • Sold $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/19/2025.
  • Sold $1,001 – $15,000 in shares of Diageo (NYSE:DEO) on 3/19/2025.
  • Sold $1,001 – $15,000 in shares of Shopify (NYSE:SHOP) on 3/19/2025.
  • Sold $1,001 – $15,000 in shares of Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk (NYSE:TLK) on 3/19/2025.
  • Sold $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 3/19/2025.
  • Sold $1,001 – $15,000 in shares of D.R. Horton (NYSE:DHI) on 3/19/2025.

Tandem Diabetes Care Price Performance

Shares of TNDM opened at $17.06 on Monday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The firm has a market cap of $1.13 billion, a PE ratio of -8.84 and a beta of 1.52. The firm’s 50 day moving average price is $23.62 and its 200 day moving average price is $30.82. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TNDM. Captrust Financial Advisors lifted its holdings in shares of Tandem Diabetes Care by 19.3% during the 3rd quarter. Captrust Financial Advisors now owns 10,170 shares of the medical device company’s stock worth $431,000 after acquiring an additional 1,647 shares during the period. Quantinno Capital Management LP boosted its holdings in Tandem Diabetes Care by 43.1% during the third quarter. Quantinno Capital Management LP now owns 31,145 shares of the medical device company’s stock valued at $1,321,000 after purchasing an additional 9,385 shares in the last quarter. Stifel Financial Corp raised its holdings in shares of Tandem Diabetes Care by 6.8% in the 3rd quarter. Stifel Financial Corp now owns 34,072 shares of the medical device company’s stock worth $1,445,000 after buying an additional 2,160 shares in the last quarter. State Street Corp boosted its stake in Tandem Diabetes Care by 3.2% in the 3rd quarter. State Street Corp now owns 2,655,736 shares of the medical device company’s stock valued at $112,630,000 after buying an additional 83,172 shares in the last quarter. Finally, M&T Bank Corp grew its position in Tandem Diabetes Care by 1.7% in the third quarter. M&T Bank Corp now owns 51,835 shares of the medical device company’s stock valued at $2,199,000 after acquiring an additional 858 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Mizuho began coverage on shares of Tandem Diabetes Care in a report on Thursday. They set a “neutral” rating and a $20.00 price target on the stock. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $22.00 price target (down previously from $38.00) on shares of Tandem Diabetes Care in a research report on Monday, March 3rd. Morgan Stanley downgraded Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $45.00 to $22.00 in a research note on Wednesday, March 5th. Barclays reduced their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Finally, The Goldman Sachs Group lowered their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Nine research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.88.

Get Our Latest Research Report on Tandem Diabetes Care

Insiders Place Their Bets

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of the business’s stock in a transaction dated Friday, March 7th. The stock was bought at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the purchase, the chief operating officer now owns 10,538 shares of the company’s stock, valued at approximately $190,948.56. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.20% of the company’s stock.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Tandem Diabetes Care Company Profile

(Get Free Report)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

Featured Stories

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.